Blockade of both α1A- and α1B-adrenergic receptor subtype signaling is required to inhibit neointimal formation in the mouse femoral artery

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 1, 2007, Pages

  Hosoda, Chihiro ^a,b   Hiroyama, Masami ^a   Sanbe, Atsushi ^a   Birumachi, Jun Ichi ^a   Kitamura, Tadaichi ^b   Cotecchia, Susanna ^c   Simpson, Paul C ^d,e   Tsujimoto, Gozoh ^f   Tanoue, Akito ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Femoral artery of mouse; Smooth muscle cell; Vascular injury; Wire injury; 1 adrenergic receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1C ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR ALPHA(1A); ADRENERGIC RECEPTOR ALPHA(1B); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; CONTROLLED STUDY; FEMORAL ARTERY; INTIMA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RESTENOSIS; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; INJURY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; FEMORAL ARTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 34547095988     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00626.2006     Document Type: Article

References (42)

1. Adriaensen H, Vryens R. Prazosin in the treatment of hypertension. Practitioner 214: 268-273, 1975.
2. Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA, Waltenberger J, De Maat MP, Frants RR, Atsma DE, Van Der Laarse A, Van Der Wall EE, Jukema JW. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 25: 1163-1170, 2004.
3. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283: 1967-1975, 2000.
4. Andrassy M, Belov D, Harja E, Shan Zou Y, Leitges M, Katus HA, Nawroth PP, Du Yan S, Marie Schmidt A, Yan SF. Central role of PKC-β in neointimal expansion triggered by acute arterial injury. Circ Res 96: 476-483, 2005.
5. Baim DS, Kasper DL, Braunwald E, Fauci A, Hauser S, Longo D, Jameson JL. Percutaneus coronary revascularization. In: Harrison's Principles of Internal Medicine (16th ed.). New York: McGraw-Hill, 2005, p. 1459-1462.
6. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8: 987-994, 2002.
7. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, Mostardini M, Schmidt A, Beermann F, Cotecchia S. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA 94: 11589-11594, 1997.
8. Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol 21: 83-90, 1986.
9. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Wong SC, Leon MB. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 26: 720-724, 1995.
10. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)- adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 283: H1577-H1587, 2002.
11. Faber JE, Yang N, Xin X. Expression of alpha-adrenoceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther 298: 441-452, 2001.
12. Fingerle J, Sanders KH, Fotev Z. Alpha 1-receptor antagonists urapidil and prazosin inhibit neointima formation in rat carotid artery induced by balloon catheter injury. Basic Res Cardiol 86: 75-81, 1991.
13. Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M, Bossi IM, Cassagneau B, Fajadet J, Di Mario C, Albiero R, Cugno M, Grossi A, Heusch G. Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 106: 2901-2907, 2002.
14. Hosoda C, Koshimizu TA, Tanoue A, Nasa Y, Oikawa R, Tomabechi T, Fukuda S, Shinoura H, Oshikawa S, Takeo S, Kitamura T, Cotecchia S, Tsujimoto G. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 67: 912-922, 2005a.
15. Hosoda C, Tanoue A, Shibano M, Tanaka Y, Hiroyama M, Koshimizu TA, Cotecchia S, Kitamura T, Tsujimoto G, Koike K. Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice. Br J Pharmacol 146: 456-466, 2005b.
16. Israilova M, Tanaka T, Suzuki F, Morishima S, Muramatsu I. Pharmacological characterization and cross talk of alpha1a- and alpha1b-adrenoceptors coexpressed in human embryonic kidney 293 cells. J Pharmacol Exp Ther 309: 259-266, 2004.
17. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 44: 733-739, 2004.
18. Lasagna L. Diuretics vs. α-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 283: 2013-2014, 2000.
19. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 101: 1225-1232, 1998.
20. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E, Simpson PC. The alpha (1A/C)- and alpha (1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 111: 1783-1791, 2003.
21. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 22: 934-939, 2002.
22. Reid JL, Vincent J. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists. Cardiology 73: 164-174, 1986.
23. Reidy MA, Clowes AW, Schwartz SM. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 49: 569-575, 1983.
24. Rokosh DG, Simpson PC. Knockout of the α1A/C-adrenergic receptor subtype: the α1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99: 9474-9479, 2002.
25. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimon JJ, Charo IF, Taubman MB. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 22: 554-559, 2002.
26. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100: 2336-2343, 1999.
27. Sabath DE, Broome HE, Prystowsky MB. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 91: 185-191, 1990.
28. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 32: 2097-2104, 2000.
29. Scholten C, Schemper M, Probst P, Maurer G, Stefenelli T. Predictors of early reangiography within 30 days after coronary stenting. Can J Cardiol 19: 1503-1508, 2003.
30. Squadrito F, Minutoli L, Esposito M, Bitto A, Marini H, Seminara P, Crisafulli A, Passaniti M, Adamo EB, Marini R, Guarini S, Altavilla D. Lipid peroxidation triggers both c-Jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK) activation and neointimal hyperplasia induced by cessation of blood flow in the mouse carotid artery. Atherosclerosis 178: 295-302, 2005.
31. Sun D, Huang A, Mital S, Kichuk MR, Marboe CC, Addonizio LJ, Michler RE, Koller A, Hintze TH, Kaley G. Norepinephrine elicits beta2-receptor-mediated dilation of isolated human coronary arterioles. Circulation 106: 550-555, 2002.
32. Suzuki J, Iwai M, Nakagami H, Wu L, Chen R, Sugaya T, Hamada M, Hiwada K, Horiuchi M. Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106: 847-853, 2002.
33. Tacken PJ, Delsing DJ, Gijbels MJ, Quax PH, Havekes LM, Hofker MH, van Dijk KW. VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area. Atherosclerosis 162: 103-110, 2002.
34. 1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 109: 765-775, 2002a.
35. Tanoue A, Koba M, Miyawaki S, Koshimizu TA, Hosoda C, Oshikawa S, Tsujimoto G. Role of the alpha1D-adrenergic receptor in the development of salt-induced hypertension. Hypertension 40: 101-106, 2002b.
36. Teeters JC, Erami C, Zhang H, Faber JE. Systemic alpha 1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery. Am J Physiol Heart Circ Physiol 284: H385-H392, 2003.
37. Uberti MA, Hall RA, Minneman KP. Subtype-specific dimerization of alpha 1-adrenoceptors: effects on receptor expression and pharmacological properties. Mol Pharmacol 64: 1379-1390, 2003.
38. Walker RG, Whitworth JA, Saines D, Kincaid-Smith P. Prazosin. Long-term treatment of moderate and severe hypertension and lack of "tolerance". Med J Aust 2: 146-147, 1981.
39. Xiao D, Longo LD, Zhang L. Alpha1-adrenoceptor-mediated phosphorylation of MYPT1 and CPI-17 in the uterine artery: role of ERK/PKC. Am J Physiol Heart Circ Physiol 288: H2828-H2835, 2005.
40. Yuan Y, Liao L, Tulis DA, Xu J. Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation 105: 2653-2659, 2002.
41. Zhang H, Cotecchia S, Thomas SA, Tanoue A, Tsujimoto G, Faber JE. Gene deletion of dopamine beta-hydroxylase and alpha1-adrenoceptors demonstrates involvement of catecholamines in vascular remodeling. Am J Physiol Heart Circ Physiol 287: H2106-H2114, 2004.
42. Zhong H, Minneman KP. Alpha1-adrenoceptor subtypes. Eur J Pharmacol 375: 261-276, 1999.